OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Bernice Matusow, Sadegh Saghafinia, Pei Pei Li, Amanda Kohler, Pan-Yu Chen, Christine Nichols, Parmveer Singh, Kerry Inokuchi, Jackie M. Walling, Gideon Bollag
Institution: Opna Bio (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405040216